Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

TB Still a Major International Killer

By Drug Discovery Trends Editor | March 29, 2016

Dr Nick West. Source: University of QueenslandTuberculosis: Many Australians believe it was eradicated years ago – but the grim reality is that TB is still a major world-wide killer, responsible for 1.5 million deaths a year.

Today is World Tuberculosis Day, but every day is TB day for University of Queensland researcher Dr Nick West, as he battles to combat a disease that kills someone every 21 seconds.

“A lot of people think TB was only a problem when their grandparents were young but, sadly, that couldn’t be further from the truth,” Dr West said.

“Despite a concerted international effort, there were 9.6 million new cases of TB in 2014, resulting in 1.5 million deaths. And one in three people globally is infected with TB.

Dr West, the founder and Laboratory Head of the Tuberculosis Research Laboratory in UQ’s School of Chemistry and Molecular Biosciences, said TB, caused by the bacteria Mycobacterium tuberculosis, was highly contagious and could be spread from person to person simply by breathing.

“When a person sick with TB coughs or sneezes, little droplets containing the bacteria can float through the air, allowing them to be easily inhaled by others,” Dr West said.

He said intensified research efforts have resulted in new vaccine strategies, new candidate antibiotics and rapid diagnostics that suggest that one of the oldest human infections could be beaten.

“Any successful anti-TB strategy has three pillars – prevention, diagnosis and treatment,” Dr West said.

“My team and I are contributing to all three areas, using modern genomic technologies to gain a better understanding of how bacteria actually cause TB.

“In the past few years we’ve made huge progress in this area.

“We’re now in the process of translating our discoveries into practical solutions such as new therapies and control measures.”

Source: University of Queensland


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50